Clinical trials: Hormone Refractory
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University
Prostate Cancer
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment.
- Trial name
- NCT00183937
- Testing
- PS 341, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Prostatic Neoplasms, Prostate Cancer
Fulvestrant in Hormone Refractory Prostate Cancer
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have…
- Trial name
- NCT00476645
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Prostate Cancer
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Docetaxel-based therapy has been shown to prolong survival as first-line therapy for patients with hormone refractory prostate cancer (HRPC), and has become the standard of care.
- Trial name
- NCT00216099
- Testing
- Pemetrexed, Folic Acid, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Christopher Sweeney, MBBS
Prostate Cancer
A Study of Pertuzumab in Participants With Prostate Cancer
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
- Trial name
- NCT02480010
- Testing
- Pertuzumab
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
The purpose of this study is to test the safety of ketoconazole and how well it works after chemotherapy has been used. Ketoconazole at lower doses has been used for fungal infections however has not yet been approved by the Food…
- Trial name
- NCT00895310
- Testing
- Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
Metastatic Prostate Cancer
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic hormone-refractory prostate cancer.
- Trial name
- NCT00452387
- Testing
- Mitoxantrone, Prednisone, Sorafenib
- Where
- 10 sites in United States
- Volunteers
- 22 people
- Sponsor
- Accelerated Community Oncology Research Network
Prostate Cancer
Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.
- Trial name
- INV342 (NCT00427999)
- Testing
- imatinib mesylate, Treosulfane, etoricoxib
- Where
- 10 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Novartis Pharmaceuticals
Hormone Refractory Prostate Cancer
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
- Trial name
- NCT00629525
- Testing
- RAD001
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Daniel George, MD
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
This phase II trial is studying how well AZD0530 works in treating patients with prostate cancer that did not respond to hormone therapy.
- Trial name
- NCT00513071
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00483561
- Testing
- Gefitinib plus etoposide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Nebraska
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters)…
- Conditions
- Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT01487863
- Testing
- sipuleucel-T, abiraterone acetate
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Dendreon
Prostate Cancer
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
- Trial name
- NCT00642018
- Testing
- docetaxel, LY2181308 sodium, Prednisone
- Where
- 17 sites in United States, Germany and 2 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00118092
- Testing
- tanespimycin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
This study is for patients with cancer of the prostate gland that has metastasized or spread outside the prostate to other parts of the body.
- Trial name
- NCT00327340
- Testing
- custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Achieve Life Sciences
Prostate Neoplasms
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
- Trial name
- NCT00473746
- Testing
- Abiraterone acetate, prednisone/prednisolone or dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Janssen Research & Development, LLC